GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Total Debt per Share

TARA (Protara Therapeutics) Total Debt per Share : $0.23 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Total Debt per Share?

$0.23 (As of Sep. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Protara Therapeutics's Total Debt Per Share for the quarter that ended in Sep. 2024 was $0.23.

Protara Therapeutics Total Debt per Share Historical Data

The historical data trend for Protara Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics Total Debt per Share Chart

Protara Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Debt per Share
Get a 7-Day Free Trial - 0.10 0.64 0.57 0.48

Protara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.48 0.46 0.24 0.23

Protara Therapeutics Total Debt per Share Calculation

Protara Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(4.48+0.98)/11.36
=0.48

Protara Therapeutics's Total Debt Per Share for the quarter that ended in Sep. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(3.66+1.08)/20.63
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protara Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Total Debt per Share
Comparable Companies
MBRX FWPAY VBIV APRE SNSE ONTX OCEL CALC NNVC GOVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1KPA:Germany
Address
345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Website
http://www.protaratx.com
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Jesse Shefferman director, officer: CEO and President C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry officer: VP, Controller 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari officer: Chief Medical Officer C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo officer: Chief Medical Officer C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall 10 percent owner C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly director ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy officer: Chief Medical Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo officer: Sr. Vice President, Research C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014